MET blocks the proliferation of triple-negative breast cancer cells through the p21 cyclin-dependent inhibitory kinase pathway [147], and the peptide induces apoptosis in tumor cells and inhibits cervical carcinoma progression [159]. The gene discussed is CDKN1A; the disease is triple-negative breast carcinoma.